{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:45:31Z","timestamp":1790178331720,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicon"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.toxicon.2020.02.020","type":"journal-article","created":{"date-parts":[[2020,3,14]],"date-time":"2020-03-14T11:29:57Z","timestamp":1584185397000},"page":"84-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Clinical duration of action of different botulinum toxin types in humans"],"prefix":"10.1016","volume":"179","author":[{"given":"Roberto","family":"Eleopra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Rinaldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Montecucco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ornella","family":"Rossetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Devigili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.toxicon.2020.02.020_bib1","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1007\/s00415-015-7703-x","article-title":"Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement","volume":"262","author":"Albanese","year":"2015","journal-title":"J. Neurol."},{"key":"10.1016\/j.toxicon.2020.02.020_bib2","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/mds.26384","article-title":"Therapeutic advances in dystonia","volume":"30","author":"Albanese","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2020.02.020_bib53","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1097\/DSS.0000000000000429","article-title":"Comparison of onabotulinumtoxinA and rimabotulinumtoxinB for the treatment of axillary hyperhidrosis","volume":"41","author":"An","year":"2015","journal-title":"Dermatol. Surg."},{"key":"10.1016\/j.toxicon.2020.02.020_bib3","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/0306-4522(90)90109-H","article-title":"Terminal sprouting in mouse neuromuscular junctions poisoned with botulinum type A toxin: morphological and electrophysiological features","volume":"37","author":"Angaut-Petit","year":"1990","journal-title":"Neuroscience"},{"key":"10.1016\/j.toxicon.2020.02.020_bib4","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1111\/j.1468-1331.1999.tb00032.x","article-title":"Preclinical update on BOTOX (botulinum toxin type A)-purified neurotoxin complex relative to other botulinum neurotoxin preparations","volume":"6","author":"Aoki","year":"1999","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.toxicon.2020.02.020_bib5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.toxicon.2015.08.001","article-title":"Clinical differences between botulinum neurotoxin type A and B","volume":"107","author":"Bentivoglio","year":"2015","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2020.02.020_bib6","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1212\/WNL.53.7.1439","article-title":"Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia","volume":"53","author":"Brashear","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2020.02.020_bib7","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/S0149-2918(00)83049-0","article-title":"Duration of effect of botulinum toxin type A in adult patients with cervical dystonia: a retrospective chart review","volume":"22","author":"Brashear","year":"2000","journal-title":"Clin. Therapeut."},{"key":"10.1016\/j.toxicon.2020.02.020_bib8","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1212\/WNL.53.7.1431","article-title":"Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia","volume":"53","author":"Brin","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2020.02.020_bib9","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1212\/WNL.51.5.1494","article-title":"Botulinum toxin type F for treatment of dystonia: long-term experience","volume":"51","author":"Chen","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2020.02.020_bib10","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1212\/01.wnl.0000183055.81056.5c","article-title":"Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia","volume":"65","author":"Comella","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2020.02.020_bib11","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1073\/pnas.96.6.3200","article-title":"Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals","volume":"96","author":"de Paiva","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.toxicon.2020.02.020_bib12","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/BF03033929","article-title":"Clinical use of non-A botulinum toxins: botulinum toxin type B","volume":"9","author":"Dressler","year":"2006","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.toxicon.2020.02.020_bib13","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/14737175.2017.1262258","article-title":"Immunological aspects of botulinum toxin therapy","volume":"17","author":"Dressler","year":"2017","journal-title":"Expert Rev. Neurother."},{"issue":"10","key":"10.1016\/j.toxicon.2020.02.020_bib14","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s00702-019-02029-5","article-title":"Botulinum toxin type D blocks autonomic cholinergic synapses in humans: discussion of a potential therapeutic use","volume":"126","author":"Dressler","year":"2019","journal-title":"J. Neural. Transm. (Vienna)"},{"key":"10.1016\/j.toxicon.2020.02.020_bib15","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1469-8749.1999.tb00589.x","article-title":"The effect of botulinum toxin A on gastrocnemius length: magnitude and duration of response","volume":"41","author":"Eames","year":"1999","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.toxicon.2020.02.020_bib16","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1212\/WNL.46.4.1158","article-title":"Botulinum toxin treatment in the facial muscles of humans: evidence of an action in untreated near muscles by peripheral local diffusion","volume":"46","author":"Eleopra","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2020.02.020_bib17","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/mds.870120115","article-title":"The variability in the clinical effect induced by botulinum toxin type A: the role of muscle activity in humans","volume":"12","author":"Eleopra","year":"1997","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2020.02.020_bib18","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0304-3940(97)13448-6","article-title":"Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human","volume":"224","author":"Eleopra","year":"1997","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.toxicon.2020.02.020_bib19","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0304-3940(98)00775-7","article-title":"Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans","volume":"256","author":"Eleopra","year":"1998","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.toxicon.2020.02.020_bib20","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S1388-2457(02)00103-7","article-title":"Botulinum neurotoxin serotypes A and C do not affect motor units survival in humans: an electrophysiological study by motor units counting","volume":"113","author":"Eleopra","year":"2002","journal-title":"Clin. Neurophysiol."},{"issue":"Suppl. 8","key":"10.1016\/j.toxicon.2020.02.020_bib21","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1002\/mds.20010","article-title":"Different types of botulinum toxin in humans","volume":"19","author":"Eleopra","year":"2004","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2020.02.020_bib22","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/BF03033930","article-title":"Clinical use of non-A botulinum toxins: botulinum toxin type C and botulinum toxin type","volume":"9","author":"Eleopra","year":"2006","journal-title":"F. Neurotox Res."},{"key":"10.1016\/j.toxicon.2020.02.020_bib23","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.clinph.2012.11.004","article-title":"Botulinum neurotoxin serotype D is poorly effective in humans: an in vivo electrophysiological study","volume":"124","author":"Eleopra","year":"2013","journal-title":"Clin. Neurophysiol."},{"key":"10.1016\/j.toxicon.2020.02.020_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/toxins10110448","article-title":"AbobotulinumtoxinA: a new therapy for hip osteoarthritis","volume":"vol. 10","author":"Eleopra","year":"2018","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2020.02.020_bib25","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2147\/TCRM.S99239","article-title":"Considerations on patient-related outcomes with the use of botulinum toxins: is switching products safe?","volume":"12","author":"Fraint","year":"2016","journal-title":"Therapeut. Clin. Risk Manag."},{"key":"10.1016\/j.toxicon.2020.02.020_bib26","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/mds.870080411","article-title":"Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A","volume":"8","author":"Greene","year":"1993","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2020.02.020_bib27","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/mds.870110211","article-title":"Response to botulinum toxin F in seronegative botulinum toxin A--resistant patients","volume":"11","author":"Greene","year":"1996","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2020.02.020_bib52","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mds.23473","article-title":"Botulinum toxin A versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson\u2019s disease","volume":"26","author":"Guidubaldi","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2020.02.020_bib28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/1531-8249(200007)48:1<7::AID-ANA2>3.0.CO;2-O","article-title":"How does botulinum toxin work?","volume":"48","author":"Hallett","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.toxicon.2020.02.020_bib29","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.toxicon.2012.12.004","article-title":"Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders","volume":"67","author":"Hallett","year":"2013","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2020.02.020_bib30","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/mus.880171207","article-title":"Serial neurophysiological studies of intramuscular botulinum-A toxin in humans","volume":"17","author":"Hamjian","year":"1994","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.toxicon.2020.02.020_bib32","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1136\/jnnp.64.5.577","article-title":"Further studies using higher doses of botulinum toxin type F for torticollis resistant to botulinum toxin type A","volume":"64","author":"Houser","year":"1998","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.toxicon.2020.02.020_bib33","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/jnnp.53.8.633","article-title":"Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm","volume":"53","author":"Jankovic","year":"1990","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.toxicon.2020.02.020_bib34","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1212\/WNL.45.9.1743","article-title":"Response and immunoresistance to botulinum toxin injections","volume":"45","author":"Jankovic","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2020.02.020_bib35","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.toxicon.2017.09.004","article-title":"Longitudinal studies of botulinum toxin in cervical dystonia: why do patients discontinue therapy?","volume":"147","author":"Jinnah","year":"2018","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2020.02.020_bib36","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00702-014-1278-z","article-title":"Blepharospasm: long-term treatment with either botox(R), xeomin(R) or dysport(R)","volume":"122","author":"Kollewe","year":"2015","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.toxicon.2020.02.020_bib37","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2133.2010.10085.x","article-title":"Long-term efficacy and respective potencies of botulinum toxin A and B: a randomized, double-blind study","volume":"164","author":"Kranz","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.toxicon.2020.02.020_bib38","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1586\/ern.09.134","article-title":"Temporal Characteristics of botulinum neurotoxin therapy","volume":"10","author":"Lebeda","year":"2010","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.toxicon.2020.02.020_bib39","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJM199201303260516","article-title":"Therapeutic use of type F botulinum toxin","volume":"326","author":"Ludlow","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.toxicon.2020.02.020_bib40","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1212\/WNL.45.3.506","article-title":"Comparison of therapeutic efficacies of type A and F botulinum toxins for blepharospasm: a double-blind, controlled study","volume":"45","author":"Mezaki","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2020.02.020_bib41","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/1531-8257(199911)14:6<1017::AID-MDS1018>3.0.CO;2-3","article-title":"Combined use of type A and F botulinum toxins for blepharospasm: a double-blind controlled trial","volume":"14","author":"Mezaki","year":"1999","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2020.02.020_bib42","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1212\/01.wnl.0000311390.87642.d8","article-title":"Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and technology assessment subcommittee of the American academy of neurology","volume":"70","author":"Naumann","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2020.02.020_bib43","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.toxicon.2015.07.001","article-title":"Clinical comparison of botulinum toxin in motor and autonomic disorders: similarities and differences","volume":"107","author":"Naumann","year":"2015","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2020.02.020_bib44","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.21724","article-title":"Botulinum toxin type B vs. type A in toxin-naive patients with cervical dystonia: randomized, double-blind, noninferiority trial","volume":"23","author":"Pappert","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2020.02.020_bib45","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.toxicon.2015.08.014","article-title":"Botulinum Toxin A and B in sialorrhea: long-term data and literature overview","volume":"107","author":"Petracca","year":"2015","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2020.02.020_bib46","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1124\/pr.116.012658","article-title":"Botulinum neurotoxins: biology, pharmacology, and toxicology","volume":"69","author":"Pirazzini","year":"2017","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.toxicon.2020.02.020_bib47","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrmicro3295","article-title":"Botulinum neurotoxins: genetic, structural and mechanistic insights","volume":"12","author":"Rossetto","year":"2014","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.toxicon.2020.02.020_bib48","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/jnnp.59.6.601","article-title":"Botulinum toxin F in the treatment of torticollis clinically resistant to botulinum toxin A","volume":"59","author":"Sheean","year":"1995","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.toxicon.2020.02.020_bib49","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1212\/01.wnl.0000311389.26145.95","article-title":"Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American academy of neurology","volume":"70","author":"Simpson","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2020.02.020_bib50","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.49.1.189","article-title":"Human response to botulinum toxin injection: type B compared with type A","volume":"49","author":"Sloop","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2020.02.020_bib51","author":"Smith","year":"1988"}],"container-title":["Toxicon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010120300659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010120300659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:15:15Z","timestamp":1758575715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041010120300659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":52,"alternative-id":["S0041010120300659"],"URL":"https:\/\/doi.org\/10.1016\/j.toxicon.2020.02.020","relation":{},"ISSN":["0041-0101"],"issn-type":[{"value":"0041-0101","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical duration of action of different botulinum toxin types in humans","name":"articletitle","label":"Article Title"},{"value":"Toxicon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxicon.2020.02.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}